Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Idec Reports First Tysabri PML Case In U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

Report is “not unexpected,” FDA says, but adverse event is not yet a non-event for Biogen and Elan.

You may also be interested in...



Tysabri Sales Dip But Don’t Swoon After PML Adverse Events

Biogen plans to report further progressive multifocal leukoencephalopathy cases only when “they provide substantial new information,” CEO Mullen says.

Safety Panic: Tysabri, Byetta and the Challenge of Risk Communication on Wall Street

There is no question someone is over-reacting to safety issues with Biogen Idec/Elan's Tysabri and Lilly/Amylin's Byetta. But is it FDA-or investors?

FDA Still Behind Tysabri Monotherapy

Medwatch warning is less strident than some feared.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel